Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network

Sneha Suresh; Joseline Zafack; Anne Pham-Huy; Beata Derfalvi; Manish Sadarangani; Athena McConnell; Bruce Tapiéro; Scott A. Halperin; Gaston De Serres; Jeffrey M Pernica; Karina A. Top

doi:10.1186/s13223-022-00667-1

Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network

Sneha Suresh, Joseline Zafack, Anne Pham-Huy, Beata Derfalvi, Manish Sadarangani, Athena McConnell, Bruce Tapiéro, Scott A. Halperin, Gaston De Serres, Jeffrey M Pernica, Karina A. Top

Medicine

Résultat de recherche: Article › examen par les pairs

1 Citation (Scopus)

Résumé

Background and objectives: Safety and effectiveness concerns may preclude physicians from recommending vaccination in mild/moderate inborn errors of immunity (IEI). This study describes attitudes and practices regarding vaccination among physicians who care for patients with mild/moderate B cell or mild/moderate combined immunodeficiencies (CID) and vaccination completeness among patients diagnosed with IEIs. Methods: Canadian physicians caring for children with IEI were surveyed about attitudes and practices regarding vaccination in mild/moderate IEI. Following informed consent, immunization records of pediatric patients with IEI evaluated before 7 years of age were reviewed. Vaccine completeness was defined at age 2 years as 4 doses of diphtheria-tetanus-pertussis (DTaP), 3 doses pneumococcal conjugate (PCV), and 1 dose measles-mumps-rubella (MMR) vaccines. At 7 years 5 doses of DTP and 2 doses MMR were required. Results: Forty-five physicians from 8 provinces completed the survey. Most recommended inactivated vaccines for B cell deficiency: (84% (38/45) and CID (73% (33/45). Fewer recommended live attenuated vaccines (B cell: 53% (24/45), CID 31% (14/45)). Of 96 patients with IEI recruited across 7 centers, vaccination completeness at age 2 was 25/43 (58%) for predominantly antibody, 3/13 (23%) for CID, 7/35 (20%) for CID with syndromic features, and 4/4 (100%) for innate/phagocyte defects. Completeness at age 7 was 15%, 17%, 5%, and 33%, respectively. Conclusion: Most physicians surveyed recommended inactivated vaccines in children with mild to moderate IEI. Vaccine completeness for all IEI was low, particularly at age 7. Further studies should address the reasons for low vaccine uptake among children with IEI and whether those with mild-moderate IEI, where vaccination is recommended, eventually receive all indicated vaccines.

Langue d'origine	English
Numéro d'article	32
Journal	Allergy, Asthma and Clinical Immunology
Volume	18
Numéro de publication	1
DOI	https://doi.org/10.1186/s13223-022-00667-1
Statut de publication	Published - déc. 2022

Note bibliographique

Funding Information:
KAT has received consultancy fees from Pfizer and grants from GSK unrelated to the submitted work. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. None of the other authors have conflicts of interests or financial disclosures.

Funding Information:
The study was funded by the Canadian Institutes of Health Research and Public Health Agency of Canada through the Canadian Immunization Research Network.

Publisher Copyright:
© 2022, The Author(s).

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

PubMed: MeSH publication types

Journal Article

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1186/s13223-022-00667-1

Autres fichiers et liens

Empreinte numérique

Plonger dans les sujets de recherche 'Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network'. Ensemble, ils forment une empreinte numérique unique.

Citer

Suresh, S., Zafack, J., Pham-Huy, A., Derfalvi, B., Sadarangani, M., McConnell, A., Tapiéro, B., Halperin, S. A., De Serres, G., M Pernica, J., & Top, K. A. (2022). Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network. Allergy, Asthma and Clinical Immunology, 18(1), Article 32. https://doi.org/10.1186/s13223-022-00667-1

Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network. / Suresh, Sneha; Zafack, Joseline; Pham-Huy, Anne et al.
Dans: Allergy, Asthma and Clinical Immunology, Vol. 18, N° 1, 32, 12.2022.

Résultat de recherche: Article › examen par les pairs

Suresh, S, Zafack, J, Pham-Huy, A, Derfalvi, B, Sadarangani, M, McConnell, A, Tapiéro, B, Halperin, SA, De Serres, G, M Pernica, J & Top, KA 2022, 'Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network', Allergy, Asthma and Clinical Immunology, vol. 18, n° 1, 32. https://doi.org/10.1186/s13223-022-00667-1

@article{68985a00c68a4c599d75ab4a57ddf473,

title = "Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network",

abstract = "Background and objectives: Safety and effectiveness concerns may preclude physicians from recommending vaccination in mild/moderate inborn errors of immunity (IEI). This study describes attitudes and practices regarding vaccination among physicians who care for patients with mild/moderate B cell or mild/moderate combined immunodeficiencies (CID) and vaccination completeness among patients diagnosed with IEIs. Methods: Canadian physicians caring for children with IEI were surveyed about attitudes and practices regarding vaccination in mild/moderate IEI. Following informed consent, immunization records of pediatric patients with IEI evaluated before 7 years of age were reviewed. Vaccine completeness was defined at age 2 years as 4 doses of diphtheria-tetanus-pertussis (DTaP), 3 doses pneumococcal conjugate (PCV), and 1 dose measles-mumps-rubella (MMR) vaccines. At 7 years 5 doses of DTP and 2 doses MMR were required. Results: Forty-five physicians from 8 provinces completed the survey. Most recommended inactivated vaccines for B cell deficiency: (84% (38/45) and CID (73% (33/45). Fewer recommended live attenuated vaccines (B cell: 53% (24/45), CID 31% (14/45)). Of 96 patients with IEI recruited across 7 centers, vaccination completeness at age 2 was 25/43 (58%) for predominantly antibody, 3/13 (23%) for CID, 7/35 (20%) for CID with syndromic features, and 4/4 (100%) for innate/phagocyte defects. Completeness at age 7 was 15%, 17%, 5%, and 33%, respectively. Conclusion: Most physicians surveyed recommended inactivated vaccines in children with mild to moderate IEI. Vaccine completeness for all IEI was low, particularly at age 7. Further studies should address the reasons for low vaccine uptake among children with IEI and whether those with mild-moderate IEI, where vaccination is recommended, eventually receive all indicated vaccines.",

author = "Sneha Suresh and Joseline Zafack and Anne Pham-Huy and Beata Derfalvi and Manish Sadarangani and Athena McConnell and Bruce Tapi{\'e}ro and Halperin, {Scott A.} and {De Serres}, Gaston and {M Pernica}, Jeffrey and Top, {Karina A.}",

note = "Funding Information: KAT has received consultancy fees from Pfizer and grants from GSK unrelated to the submitted work. MS is supported via salary awards from the BC Children{\textquoteright}s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. None of the other authors have conflicts of interests or financial disclosures. Funding Information: The study was funded by the Canadian Institutes of Health Research and Public Health Agency of Canada through the Canadian Immunization Research Network. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s13223-022-00667-1",

language = "English",

volume = "18",

journal = "Allergy, Asthma and Clinical Immunology",

issn = "1710-1484",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI

T2 - results from the Canadian Immunization Research Network

AU - Suresh, Sneha

AU - Zafack, Joseline

AU - Pham-Huy, Anne

AU - Derfalvi, Beata

AU - Sadarangani, Manish

AU - McConnell, Athena

AU - Tapiéro, Bruce

AU - Halperin, Scott A.

AU - De Serres, Gaston

AU - M Pernica, Jeffrey

AU - Top, Karina A.

N1 - Funding Information: KAT has received consultancy fees from Pfizer and grants from GSK unrelated to the submitted work. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. None of the other authors have conflicts of interests or financial disclosures. Funding Information: The study was funded by the Canadian Institutes of Health Research and Public Health Agency of Canada through the Canadian Immunization Research Network. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - Background and objectives: Safety and effectiveness concerns may preclude physicians from recommending vaccination in mild/moderate inborn errors of immunity (IEI). This study describes attitudes and practices regarding vaccination among physicians who care for patients with mild/moderate B cell or mild/moderate combined immunodeficiencies (CID) and vaccination completeness among patients diagnosed with IEIs. Methods: Canadian physicians caring for children with IEI were surveyed about attitudes and practices regarding vaccination in mild/moderate IEI. Following informed consent, immunization records of pediatric patients with IEI evaluated before 7 years of age were reviewed. Vaccine completeness was defined at age 2 years as 4 doses of diphtheria-tetanus-pertussis (DTaP), 3 doses pneumococcal conjugate (PCV), and 1 dose measles-mumps-rubella (MMR) vaccines. At 7 years 5 doses of DTP and 2 doses MMR were required. Results: Forty-five physicians from 8 provinces completed the survey. Most recommended inactivated vaccines for B cell deficiency: (84% (38/45) and CID (73% (33/45). Fewer recommended live attenuated vaccines (B cell: 53% (24/45), CID 31% (14/45)). Of 96 patients with IEI recruited across 7 centers, vaccination completeness at age 2 was 25/43 (58%) for predominantly antibody, 3/13 (23%) for CID, 7/35 (20%) for CID with syndromic features, and 4/4 (100%) for innate/phagocyte defects. Completeness at age 7 was 15%, 17%, 5%, and 33%, respectively. Conclusion: Most physicians surveyed recommended inactivated vaccines in children with mild to moderate IEI. Vaccine completeness for all IEI was low, particularly at age 7. Further studies should address the reasons for low vaccine uptake among children with IEI and whether those with mild-moderate IEI, where vaccination is recommended, eventually receive all indicated vaccines.

AB - Background and objectives: Safety and effectiveness concerns may preclude physicians from recommending vaccination in mild/moderate inborn errors of immunity (IEI). This study describes attitudes and practices regarding vaccination among physicians who care for patients with mild/moderate B cell or mild/moderate combined immunodeficiencies (CID) and vaccination completeness among patients diagnosed with IEIs. Methods: Canadian physicians caring for children with IEI were surveyed about attitudes and practices regarding vaccination in mild/moderate IEI. Following informed consent, immunization records of pediatric patients with IEI evaluated before 7 years of age were reviewed. Vaccine completeness was defined at age 2 years as 4 doses of diphtheria-tetanus-pertussis (DTaP), 3 doses pneumococcal conjugate (PCV), and 1 dose measles-mumps-rubella (MMR) vaccines. At 7 years 5 doses of DTP and 2 doses MMR were required. Results: Forty-five physicians from 8 provinces completed the survey. Most recommended inactivated vaccines for B cell deficiency: (84% (38/45) and CID (73% (33/45). Fewer recommended live attenuated vaccines (B cell: 53% (24/45), CID 31% (14/45)). Of 96 patients with IEI recruited across 7 centers, vaccination completeness at age 2 was 25/43 (58%) for predominantly antibody, 3/13 (23%) for CID, 7/35 (20%) for CID with syndromic features, and 4/4 (100%) for innate/phagocyte defects. Completeness at age 7 was 15%, 17%, 5%, and 33%, respectively. Conclusion: Most physicians surveyed recommended inactivated vaccines in children with mild to moderate IEI. Vaccine completeness for all IEI was low, particularly at age 7. Further studies should address the reasons for low vaccine uptake among children with IEI and whether those with mild-moderate IEI, where vaccination is recommended, eventually receive all indicated vaccines.

UR - http://www.scopus.com/inward/record.url?scp=85127976120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127976120&partnerID=8YFLogxK

U2 - 10.1186/s13223-022-00667-1

DO - 10.1186/s13223-022-00667-1

M3 - Article

C2 - 35397595

AN - SCOPUS:85127976120

SN - 1710-1484

VL - 18

JO - Allergy, Asthma and Clinical Immunology

JF - Allergy, Asthma and Clinical Immunology

IS - 1

M1 - 32

ER -